Australian telehealth platform Eucalyptus has raised a $30 million AUD Series B funding. The funding round was led by Silicon Valley-based NewView Capital, whose portfolio includes digital health companies 23andMe and Hims & Hers, with participation from existing investors Blackbird Ventures and W23, and new investor AirTree Ventures.
Eucalyptus is a vertically integrated telehealth platform in Australia, serving more than 200,000 patients. Since its founding in 2019, Eucalyptus has launched four demographic-focused brands. This new round of funding will allow the company to build out the behavioral health and chronic care modules of the platform to support brands in weight management, diabetes, and mental health.
“As Australia’s tech ecosystem grows, it’s great to see more and more talent moving from professional services to building the next generation of fast-growing tech companies,” said Christina Fa of NewView Capital, “we were immediately impressed by the high-quality team Eucalyptus has built and believe the company is well positioned to become a global leader in digital care.”
“With Eucalyptus’ continued growth throughout Australia, we are thrilled with today’s announcement,” says founder Tim Doyle, “We’re excited to have NewView on board. We wanted a partner who believed a global healthcare company could originate from Australia, who had the experience to help us get there, and were willing to roll up their sleeves to help us advance the business. We believe we’ve got that with NewView.”
With the funding, Ravi Viswanathan, Founder and Managing Partner of NewView Capital, will be joining the Eucalyptus board.
Arya has been a part of the Content & Research Team at Hrnxt.com. She is a keen observer of economic developments, emerging businesses, people in business and keeps a tab on latest happenings in the business environment.